Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Former Puma Biotechnology exec is accused of making $1.2 million from insider trading - Los Angeles Times
Puma Biotechnology falls more than 20%
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Fillable Online Puma biotechnology, inc. form s-1/a - Biotech Due Diligence Fax Email Print - pdfFiller
Puma Biotechnology
Puma Biotechnology, Inc. (PBYI) Company Information - Simply Wall St
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
PUMA BIOTECHNOLOGY, INC. : PBYI Stock Price | US74587V1070 | MarketScreener
Puma Biotechnology - Crunchbase Company Profile & Funding
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
Puma Biotechnology
Puma Biotechnology (PBYI) - 5 Price Charts 2012-2023 (History)
Puma Biotechnology
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotechnology
Puma Biotechnology
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Puma Biotechnology
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology Surging
